New antimicrobial agents for patients with Clostridium difficile infections

被引：24

作者：

Bartlett J.G. ^{[1
]}

机构：

[1] Johns Hopkins University, School of Medicine, Baltimore, MD 21205

来源：

Current Infectious Disease Reports | 2009年 / 11卷 / 1期

关键词：

Vancomycin; Metronidazole; Antimicrob Agent; Rifaximin; Fusidic Acid;

D O I：

10.1007/s11908-009-0004-8

中图分类号：

学科分类号：

摘要：

Current drug treatment of Clostridium difficile infection (CDI) focuses on metronidazole and vancomycin. Early studies showed equivalence, but more recent reports indicate that oral vancomycin is preferred for serious CDI. Recent work has demonstrated a need for new drugs due to challenges with the NAP-1 strain, which appears to cause more refractory disease that is more likely to relapse. These two distinctive facets of treatment are the most challenging. This review discusses new agents in development: antibiotics, probiotics, immune response products, and agents to bind C. difficile toxins. None are likely to be more effective than oral vancomycin for acute infection. However, several may be as effective, without causing relapse or promoting unnecessary antibiotic use for multiple conditions. The greatest promise is with agents used to interrupt relapses. In this category the leading new agents appear to be antibiotics (rifaximin, nitazoxanide, difimicin, ramoplanin), toxin-binding agents (tolevamer), probiotics (Saccharomyces boulardii and Lactobacillus ramosus), and immune agents (toxoid vaccine and hyperimmune globulin). The drugs that appear most promising based on recent trials are rifaximin, tolevamer, and difimicin, which appear promising for reducing relapses. © Current Medicine Group LLC 2009.

引用

页码：21 / 28

页数：7

共 69 条

[1]

Pepin J., Valiquette L., Gagnon S., Et al., Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027, Am J Gastroenterol, 102, pp. 2781-2788, (2007)

[2]

Bartlett J.G., Narrative review: The new epidemic of Clostridium difficile-associated enteric disease, Ann Intern Med, 145, pp. 758-764, (2006)

[3]

McDonald L.C., Killgore G.E., Thompson A., Et al., An epidemic, toxin gene-variant strain of Clostridium difficile, N Engl J Med, 353, pp. 2433-2441, (2005)

[4]

Teasley D.G., Gerding D.N., Olson M.M., Et al., Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis, Lancet, 2, pp. 1043-1046, (1983)

[5]

Wenisch C., Parschalk B., Hasenhundl M., Et al., Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea, Clin Infect Dis, 22, pp. 813-818, (1996)

[6]

Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B., A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity, Clin Infect Dis, 45, pp. 302-307, (2007)

[7]

Louie T.J., Peppe J., Watt C.K., Et al., Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea, Clin Infect Dis, 4, pp. 411-420, (2006)

[8]

Al-Nassir W.N., Sethi A.K., Nerandzic M.M., Et al., Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin, Clin Infect Dis, 47, pp. 56-62, (2008)

[9]

Bolton R.P., Culshaw M.A., Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile, Gut, 27, pp. 1169-1172, (1986)

[10]

Lamontagne F., Labbe A.C., Haeck O., Et al., Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain, Ann Surg, 245, pp. 267-272, (2007)

← 1 2 3 4 5 6 7 →